George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
In today’s market, where fear seems to be the prevailing sentiment, it's essential to look beyond short-term fluctuations. Despite today's 17% drop in ImmuPharma's share price, I've increased my stake by 420,000 shares (confirmation below), confident in the company's inherent value and promising future. Amidst the noise of misleading comments about potential placings and speculative busts, my decision is based on a firm belief in ImmuPharma's current position and trajectory - arguably, stronger and more promising than ever.
This is not just about making a statement; it's about acting on conviction. I've put my money where my mouth is, fully aware that the current share price does not reflect the true potential of ImmuPharma. Time will indeed tell, and I won't engage in debates or respond to ignorant comments. My action speaks volumes about my confidence in ImmuPharma's journey ahead. Good look to all loyal LTH.
"The date indicated below will automatically change to reflect the settlement date.
* Date Type
Share
Quantity Price Amount Status *
Order Ref.
* 01 Mar 2024 Buy IMM 420,000 0.949p £3,996.30 *Executed *
* P-020809 * IMMUPHARMA PLC
Pokerchips,
Your assertion that my comments were misleading is false and overlooks the substantial, verifiable information provided by ImmuPharma through its recent RNS announcements, on which I've based my opinions. Let's address your points with specifics:
ImmuPharma's recent fund-raising efforts, securing £1.35 million through subscriptions and a retail offer, signal robust investor faith. This move, complemented by Director Lisa Baderoon's increased stake, highlights confidence from within. CEO Tim McCarthy has been transparent about the company's pathway to financial stability through 2024, emphasising cost minimisation and strategic resource allocation.
The strategy to explore partnerships for Lupuzor's distribution outside the US is a forward-looking approach, aiming to unlock long-term revenue streams. These discussions promise not just immediate financial relief but also a broader market presence for our flagship product, Lupuzor.
However, the current share price, now hovering around 1.165p, impacts the immediate financial benefits from the Lanstead agreement. Yet, this scenario might pivot positively with the imminent update on the Phase 3 Lupuzor study by Simbec-Orion. A positive outcome here could significantly uplift the company's valuation, demonstrating the potential misalignment between the current share price and ImmuPharma's intrinsic value.
Regarding our market capitalisation, currently at approximately £4.6m, it appears extremely modest against the backdrop of ImmuPharma's ambitious projects and strategic partnerships, notably with Avion and the substantial deferred tax assets amounting to nearly £50 million. This disparity often arises from market dynamics not fully reflecting the underlying value driven by scientific progress and strategic partnerships aimed at realising the full potential of our pipeline.
The upcoming update from Simbec-Orion on the Phase 3 Lupuzor study could be a pivotal moment, recalibrating perceptions and potentially the company's market valuation. It's a reminder that the share price and market capitalisation do not always mirror a company's foundational strengths or future prospects, especially in a sector as volatile and forward-looking as biotech.
Finally, highlighting factual inaccuracies, ignorance, misleading affirmations or speculative assertions in investment discussions is not bullying but a necessary part of maintaining an informed and rational discourse. The detailed announcements from ImmuPharma provide a solid foundation for such discussions, ensuring that debates are informed by the latest and most accurate company information. Moreover, for those genuinely invested in understanding ImmuPharma's current position and future direction, reaching out directly to the company for further insights or clarifications remains an open channel.
Pokerchips, while I appreciate your concern, let's not confuse stating the obvious with insults. Exposing ignorance and groundless comments is not bullying; it's simply shedding light on reality. If you find discomfort in truth, perhaps it's worth pondering why. As for discussions, I'm open to constructive debates, but let's ensure our contributions are grounded in substance rather than unfounded and misleading comments. Let's raise the bar of discourse and be constructive, I just got tired of reading nonsense comments every day.
Lambo, instead of addressing the substance of the discussion, you seem fixated on nonensense trivialities. I'm still awaiting a constructive argument from you to engage in a meaningful debate. Let's focus on the matters at hand rather than getting sidetracked.
Pokerchips, exposing ignorance is not bullying; it's simply stating the truth. If you find it uncomfortable, perhaps it's time for some introspection. I'm still waiting for a constructive argument from you to contribute meaningfully to the discussion.
Pokerchips, rather than brushing off Warren Buffett's quotes, maybe you should've given more thought to the other one: "When ignorance finds a friend, it doesn't become wisdom; it only multiplies folly." It seems fitting considering your support for Lambo's misguided remarks.
Donovan, I concur with your perspective. Lambo's proposal is bold, but I respectfully decline. I prefer stimulating conversations. As for the bet, I accept it too and if there's no placing by the specified date, Lambo, has to agree to exit this board. Lambo, we are waiting for some constructive discussions, please stop posting silly comments.
Lambo, your fixation on my name rather than engaging with the discussion speaks volumes about your approach. Meeting up isn't a threat, but your ignorance and hostility make it unappealing. Alex Bottlier is indeed my real name (not Alex Bottle, you cannot change my name just because you did not find me on Google or you are misspelling it), but I'm not here to satisfy your curiosity. It's clear you're eager to divert attention from your lack of substantive arguments by focusing on trivial matters. If you want constructive dialogue, contribute here. Otherwise, reconsider your presence on this board. Let's elevate the discourse above baseless speculation and attacks. Btw, we do not care about your real name "Lambo" I think we all have a clear picture of who you are, a second-hand Ford Fiesta at best. Now you got a follower, good for you. "When ignorance finds a friend, it doesn't become wisdom; it only multiplies folly."
Lambo, resorting to personal threats when met with reasoned discourse only highlights the weakness of your argument and your evident ignorance. Instead of turning to aggression, why not engage in constructive dialogue? You just need to inform yourself better before that happens. If you find yourself reacting with hostility when challenged, seeking help for anger management could be beneficial. It's apparent that you're desperate for attention, but addressing that issue elsewhere would be more productive. Remember, healthy and clever debate involves exchanging ideas, not threats.
Lambo, while speculation is part of investing, it's crucial to base it on informed analysis rather than mere conjecture. ImmuPharma's recent performance doesn't automatically imply an impending placing. Jumping to conclusions without solid evidence is not only unwise but also unproductive. Let's aim for more insightful discussions based on facts and genuine analysis rather than spreading unwarranted pessimism. Btw, while we are waiting for an update, I would suggest you get some help: https://www.nhs.uk/nhs-services/mental-health-services/where-to-get-urgent-help-for-mental-health/
I completely agree with Arnold's comment. It's evident that ImmuPharma is actively progressing towards its goals, despite short-term fluctuations in its share price. Lambo, it's becoming apparent that many investors are growing weary of the repetitive, vicious, and baseless comments that you've been posting regularly. It's time to properly read all RNSs and to either contribute constructively to the discussion or refrain from spreading unnecessary negativity and false information. Let's focus on meaningful dialogue that adds value to our understanding of ImmuPharma's journey and potential. If you are desperate for attention then look elsewhere or look for professional help.
It's disappointing to see unfounded negative comments about ImmuPharma, especially when they seem to lack a solid understanding of our current position and future potential. Let's set the record straight: ImmuPharma has strategically streamlined operations to ensure financial sustainability through 2024, as detailed in our recent updates. Moreover, with Simbec-Orion on board and a clear focus on advancing the Phase 3 study for Lupuzor, our trajectory is based on solid, actionable plans, not mere speculation. It's crucial to question the motives behind these ignorant and negative assertions, particularly from individuals not invested in the company. Misleading and malicious comments serve no purpose but to create unwarranted doubt among our genuine investors. Let's stay informed and optimistic about ImmuPharma's path forward and ignore ignorant and pathetic comments.
"The stock market is designed to transfer money from the Active to the Patient." - Warren Buffett
"Be fearful when others are greedy, and be greedy when others are fearful." - Warren Buffett